Floatz logo

e7386

Gastrointestinal Tumors

Eisai Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

43 Active assets in the Gastrointestinal Tumors cohort.

Asset / SponsorPhaseRating
Capecitabine
China Medical University, China
Phase 3BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 3BB
Irinotecan
Pfizer
Phase 3BB
FLUOROURACILUM
Janssen Research & Development, LLC
Phase 3BB
Octreotide Pamoate
Federico II University
Phase 2B

View all 50 →

Same molecule, other indications

e7386 is also rated in:

colorectal neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
endometrial cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →